Loading...

SOHO 2026 Annual Meeting

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters

Showing 1,267 results.

Thumbnail for Risk Stratification Using Machine Learning Phenotypes in Acute Myeloblastic Leukemia Patients With Septic Shock

AML - 260

Risk Stratification Using Machine Learning Phenotypes in Acute Myeloblastic Leukemia Patients With Septic Shock

Aishwarya Ramesh

Poster Presenter: Aishwarya Ramesh

Thumbnail for Venetoclax-Based Therapy Is Associated With Improved Survival in Acute Myeloid Leukemia: A Large Real-World Study

AML - 283

Venetoclax-Based Therapy Is Associated With Improved Survival in Acute Myeloid Leukemia: A Large Real-World Study

Fareeha Abdulwali

Poster Presenter: Fareeha Abdulwali

Thumbnail for Integrating Molecular Profiling To Predict Immunophenotypic MRD Clearance in Acute Myeloid Leukemia

AML - 289

Integrating Molecular Profiling To Predict Immunophenotypic MRD Clearance in Acute Myeloid Leukemia

Ekaterina Motyko

Poster Presenter: Ekaterina Motyko

Thumbnail for Weekly Hypomethylating Agent and Venetoclax Combination Therapy in Myeloid Neoplasms: A Real-World Single-Center Experience in an Older, High-Comorbidity Population

AML - 292

Weekly Hypomethylating Agent and Venetoclax Combination Therapy in Myeloid Neoplasms: A Real-World Single-Center Experience in an Older, High-Comorbidity Population

Mahmood Aldapt

Poster Presenter: Mahmood Aldapt

Thumbnail for ADAM17-Driven NKG2D Ligand Shedding Defines a Leukemia-Intrinsic Immune Evasion Program That Predicts Venetoclax Resistance and Reveals MEK and PI3K As Therapeutic Vulnerabilities in AML

AML - 296

ADAM17-Driven NKG2D Ligand Shedding Defines a Leukemia-Intrinsic Immune Evasion Program That Predicts Venetoclax Resistance and Reveals MEK and PI3K As Therapeutic Vulnerabilities in AML

Abdelrahman Masheh

Poster Presenter: Abdelrahman Masheh

Thumbnail for Oral Azacitidine Maintenance vs Observation in Acute Myeloid Leukemia in First Remission: A Systematic Review and Pooled Analysis of Randomized Evidence

AML - 301

Oral Azacitidine Maintenance vs Observation in Acute Myeloid Leukemia in First Remission: A Systematic Review and Pooled Analysis of Randomized Evidence

Elias Tayar

Poster Presenter: Elias Tayar

Thumbnail for Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy

AML - 327

Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy

Gautam Pantwalawalkar

Poster Presenter: Gautam Pantwalawalkar

Thumbnail for Widening Racial and Urban-Rural Disparities in AML Mortality in the Targeted Therapy Era: A Population-Level Analysis of US Mortality Trends, 2018-2024

AML - 336

Widening Racial and Urban-Rural Disparities in AML Mortality in the Targeted Therapy Era: A Population-Level Analysis of US Mortality Trends, 2018-2024

Tapan Giri

Poster Presenter: Tapan Giri

Thumbnail for MYELOVAC: A Phase 1 Trial of a Personalized Peptide-Based Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients With Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy and Allogeneic Stem Cell Transplantation

AML - 347

MYELOVAC: A Phase 1 Trial of a Personalized Peptide-Based Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients With Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy and Allogeneic Stem Cell Transplantation

Nikolaos Spyrou

Poster Presenter: Nikolaos Spyrou